Eloxx Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Society of Nephrology (ASN) Kidney We...
August 13 2019 - 10:01AM
Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage
biopharmaceutical company dedicated to the discovery and
development of novel therapeutics to treat cystic fibrosis,
cystinosis, inherited retinal disorders, and other diseases caused
by nonsense mutations limiting production of functional proteins,
today announced that two abstracts will be presented at the
American Society of Nephrology (ASN) Kidney Week
2019 in Washington, D.C. November 5 -10, 2019.
“We are pleased to be presenting the results of
our completed renal impairment study to the scientific community at
the American Society of Nephrology Kidney Week. We believe these
results support expanding our research in the kidney beyond
cystinosis into other areas such as autosomal dominant polycystic
kidney disease where there is a high prevalence of nonsense
mutation patients,” said Dr. Gregory Williams, Chief Operating
Officer of Eloxx Pharmaceuticals. “We are rapidly advancing our
Phase 2 programs for ELX-02 in cystic fibrosis and cystinosis and
we look forward to reporting top line data from both of these
programs later this year.”
“Understanding the renal clearance of ELX-02
provides important information about the appropriate dose
adjustments for patients with renal impairment or increased
clearance,” said Dr. Tom Haverty, Consulting Nephrologist to Eloxx
Pharmaceuticals. “The daily doses of ELX-02 currently being studied
in the Phase 2 programs are consistent with those evaluated in
Phase 1 and provide steady state exposures shown to be
efficacious and safe in animal models.”
The details for the two oral ELX-02
presentations are:
Poster Session Presentation
Title: “An open label-single dose, parallel-group
study to evaluate the effects of renal impairment on the
pharmacokinetics of ELX-02: Results from subjects with mild and
moderate renal impairment” Poster Board #:
TH-PO368Presenter: Dr. Gregory Williams,
Chief Operating Officer, Eloxx
PharmaceuticalsTime: November 7, 2019 from 10:00
a.m. – 12:00 pm ET
Poster Session Presentation Title:
“Cystinosis nonsense mutation read-through mediated by ELX-02
restores protein function using in vitro and in vivo models” Poster
Board #: TH-PO813Presenter: Dr. Matthew
Goddeeris, Eloxx Pharmaceuticals Time: November 7,
2019 from 10:00 a.m. – 12:00 pm ET
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company developing novel RNA-modulating drug
candidates (designed to be eukaryotic ribosomal selective
glycosides) that are formulated to treat rare and ultra-rare
premature stop codon diseases. Premature stop codons are point
mutations that disrupt protein synthesis from messenger RNA. As a
consequence, patients with premature stop codon diseases have
reduced or eliminated protein production from the mutation bearing
allele accounting for some of the most severe phenotypes in these
genetic diseases. These premature stop codons have been identified
in over 1,800 rare and ultra-rare diseases.
Read-through therapeutic development is focused on extending
mRNA half-life and increasing protein synthesis by enabling the
cytoplasmic ribosome to read through premature stop codons to
produce full-length proteins. Eloxx’s lead investigational product
candidate, ELX-02, is a small molecule drug candidate designed to
restore production of full-length functional proteins. ELX-02 is in
the early stages of clinical development focusing on cystic
fibrosis and cystinosis. ELX-02 is an investigational drug that has
not been approved by any global regulatory body. Eloxx’s
preclinical candidate pool consists of a library of novel drug
candidates designed to be eukaryotic ribosomal selective glycosides
identified based on read-through potential. Eloxx recently
announced a new program focused on rare ocular genetic disorders.
Eloxx is headquartered in Waltham, MA, with operations in Rehovot,
Israel. For more information, please visit www.eloxxpharma.com.
Forward-Looking StatementsThis press
release contains forward-looking statements, which are generally
statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections,
and speak only as of the date they are made. We undertake no
obligation to update any forward-looking statement in light of new
information or future events, except as otherwise required by law.
Forward-looking statements involve inherent risks and
uncertainties, most of which are difficult to predict and are
generally beyond our control. Actual results or outcomes may differ
materially from those implied by the forward-looking statements as
a result of the impact of a number of factors, including: the
development of the Company’s read-through technology; the approval
of the Company’s patent applications; the Company’s ability to
successfully defend its intellectual property or obtain necessary
licenses at a cost acceptable to the Company, if at all; the
successful implementation of the Company’s research and development
programs and collaborations; the Company’s ability to obtain
applicable regulatory approvals for its current and future product
candidates; the acceptance by the market of the Company’s products
should they receive regulatory approval; the timing and success of
the Company’s preliminary studies, preclinical research, clinical
trials, and related regulatory filings; the ability of the Company
to consummate additional financings as needed; as well as those
discussed in more detail in our Annual Report on Form 10-K and our
other reports filed with the Securities and Exchange
Commission.
Contact:
Barbara Ryan 203-274-2825
barbarar@eloxxpharma.com
SOURCE: Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Apr 2023 to Apr 2024